GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.

[1]  W. Vitek,et al.  Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program. , 2010, Fertility and sterility.

[2]  M. Sherman,et al.  Recent trends in breast cancer among younger women in the United States. , 2008, Journal of the National Cancer Institute.

[3]  K. Oktay,et al.  Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Ricciarelli,et al.  Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. , 2006, Fertility and sterility.

[5]  H. Bang,et al.  Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  P. Patrizio,et al.  American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Engmann,et al.  GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. , 2005, Human reproduction.

[8]  E. Kolibianakis,et al.  A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. , 2005, Human reproduction.

[9]  Alejandro C. Arroliga,et al.  Ovarian hyperstimulation syndrome , 2005, Critical care medicine.

[10]  Z. Rosenwaks,et al.  Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Winer,et al.  Web-based survey of fertility issues in young women with breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Itskovitz‐Eldor,et al.  Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  N. Vlahos,et al.  The ovarian hyperstimulation syndrome. , 2000, Fertility and sterility.

[14]  J. Schenker.  Clinical aspects of ovarian hyperstimulation syndrome. , 1999, European journal of obstetrics, gynecology, and reproductive biology.

[15]  J. Schenker,et al.  The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. , 1997, Human reproduction.

[16]  R. Fanchin,et al.  Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. , 1996, Fertility and sterility.

[17]  V. Wiwanitkit,et al.  Ovarian hyperstimulation syndrome , 1991, The Lancet.

[18]  B. Lunenfeld,et al.  Diagnosis and Treatment of Functional Infertility , 1979 .

[19]  J. Nulsen,et al.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. , 2008, Fertility and sterility.

[20]  S. Kol.  Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. , 2004, Fertility and sterility.

[21]  A. U.S..  Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome , 2003 .

[22]  B. Hankey,et al.  Trends in breast cancer in younger women in contrast to older women. , 1994, Journal of the National Cancer Institute. Monographs.